linjc16/ctgov huggingface dataset:
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Recent advances in technologies, such as microarray and high-throughput sequencing, represented a deeper understanding of molecular biology, especially noncoding RNA (ncRNA). It was found that there are only <2 % of the total genome sequence as protein-coding genes while at least 98 % of the genome are transcribed into ncRNA. In the past, non-protein-coding RNAs were known as transcription noise, but now it is obvious that ncRNAs play a crucial regulatory role in cell differentiation and organism growth and metabolism.

Official Title
-----------------
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Doxorubicin Among Egyptian Breast Cancer Patients

Conditions
-----------------
Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metastatic and localized breast cancer patients treated with Doxorubicin among chemotherapeutic protocol. Measurable disease. Age of 18 years to 80 years. The women of childbearing age must use an effective contraception for the duration of the study. Exclusion Criteria: Breast cancer patients who had undergone radiotherapy or chemotherapy. Pregnant and lactating females. History of allergic reactions attributed to compounds of similar chemical or biologic composition to chemotherapeutic agents used. Any other medical or psychiatric condition or severe or chronic laboratory abnormality making the inclusion of the patient in the study inappropriate in the opinion of the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Breast cancer patients who developed cardiotoxic side effects in response to Doxorubicin treatment | |
| 2<br>Breast cancer patients who did not develope cardiotoxic side effects in response to Doxorubicin treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiotoxicity | Occurrence of dilated cardiomyopathy | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nephrotoxicity | Occurrence of nephrotoxicity | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Doxorubcin, Breast cancer, Cardiotoxicity, Gene polymorphism
Prevent Diabetic Kidney Disease Among Egyptians

Study Overview
=================
Brief Summary
-----------------
Study of the possibility to prevent the development of Diabetic kidney disease in type 2 diabetic patients

Detailed Description
-----------------
Study of the possible role of the SGLT2 inhibitors to prevent the development of frank type2 DM among prediabetic candidates. Study of the possible role of the SGLT2 inhibitors to prevent the development of diabetic complications, namely diabetic kidney disease, diabetic retinopathy and neuropathy.

Official Title
-----------------
The National Plan To Prevent Diabetic Kidney Disease Among Egyptians: A Prospective Multicenter Randomized Controlled Study

Conditions
-----------------
Diabetes Mellitus Without Complication

Intervention / Treatment
-----------------
* Drug: Gliflozin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diabetics,prediabetics Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases of study<br>Patients is diabetes whether recently discovered or long standing diabetes | Drug: Gliflozin<br>* to study whether the use of gliflozin prevented diabetic complications<br>|
| controls of study<br>prediabetics ,or patients with clinical manifestations of insulin resistance eg acanthosis negricans | Drug: Gliflozin<br>* to study whether the use of gliflozin prevented diabetic complications<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevention of diabetic complications | glomerular filtration rate will be measured at the beginning of the study and at the end | 5 years |
Frequency and Risk Factors of Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
to assess the frequency of acute myeloid leukemia at clinical Haematology unit of Assiute university hospital to study correlations of known risk factors and if there are new risk factors participate in increasing frequency of acute myeloid leukemia

Detailed Description
-----------------
Acute myeloid leukaemia (AML) is a rare heterogeneous disease comprising a group of hematopoietic neoplasms originating from the excessive clonal proliferation of myeloid pre- cursor cells [1]. Diagnosis of AML is based on morphological diagnosis with proliferation of blast cells ≥ 20% of bone marrow cells, flow cytometric analysis and cytogenetic abnormalities, including the t(8;21)(q22;q22), t(15;17) (q22;q12) and inv (16)(p13.1;q22) which are associated with longer remission and survival, while alterations of chromosomes 5, 7, complex karyotype and 11q23 are associated with poor response to therapy and shorter overall survival [2] The etiological agent and pathogenesis of AML are not entirely clear, only few AML cases can be accurately classified through traditional cellular morphological classification [3]It is the most common acute leukaemia in adults. It accounts for 1.3% of new cancer patients in the United States, in 2018[ 4] Some factors are well documented to increase the risk of some types of leukemia such as benzene exposure and ionizing radiation [5] increased frequency of acute myeloid leukemia has been noticed at Haematology unit so the aim of the study to assess the the frequency of acute myeloid leukemia and to evaluate the risk factors for it .

Official Title
-----------------
Frequency and Risk Factors of Acute Myeloid Leukemia at Clinical Haemtology Unit of Assiut University Hospital

Conditions
-----------------
Myeloid Leukemia

Intervention / Treatment
-----------------
* Diagnostic Test: Bone marrow aspirite for diagnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Patients(above 18 years) diagnosed as acute myeloid leukemia according to WHO diagnostic criteria Exclusion Criteria: Patients with other types of leukemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Bone marrow aspirite for diagnosis|Routine investigation of acute myeloid leukemia such as bone marrow aspirite for diagnosis ,cbc|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of acute myeloid leukemia at clinical Haemtology unit of Assiute university hospital |  | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors of acute myeloid leukemia at clinical Haemtology unit of Assiute university hospital |  | Two years |
A Comparison Study of the Maxi Move 5 (MM5) Device

Study Overview
=================
Brief Summary
-----------------
This trial aims to evaluate the added improvements from a caregiver and patient benefit perspective. The trial should identify the forces involved for the caregiver when manoeuvring the lift.

Official Title
-----------------
A Laboratory Trial to Explore the Benefits of the New Maxi Move 5 (MM5) Technology

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Device: Maxi Move 5


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For expert patient: ≥18 years Healthy male or female 80-100 kg 24 healthy volunteers (caregivers) will be recruited. They will require a strong working knowledge of passive floor lifts and patient positioning with the use of loop and clip slings. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Maxi Move 5<br>24 healthy volunteers will evaluate all 5 devices | Device: Maxi Move 5<br>* 4 comparative devices will be used to evaluate the MM5 device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1. Time to complete each transfer will be recorded | Time to complete each activity and each task within the activity will be measured in seconds. | up to 24 months | 
| 2. A detailed hierarchical task analysis (HTA) of each activity will be completed using the video recordings and experimenter field notes for each transfer to asses the number of correct placements for each device. | Correct placement will be visually controlled with the use of markers on the subject and the final positioning device (e.g chair, toilet or bed) for each transfer. This will be reported as distance from the ideal position. | up to 24 months | 
| 3. Physical load for movement of the hoist throughout the activities for each device will be measured. | Force required to complete the range of patient and hoist positioning tasks, forward, backwards, rotation movement, patient positioning etc. These forces will be used with the HTA data to calculate the amount of physical force delivered by the participants with each device and each transfer. The forces used will be presented in newton. | up to 24 months | 
| 4 Collect subjective data from the caregivers that describe, comfort, ease of use, effort and willingness to adopt in practice, etc | This will be collected by the use of questionnaires | up to 24 months | 
| 5 Subjective responses from the expert patient being transferred will be recorded | This will be collected by the use of questionnaires | up to 24 months |
Understanding COVID-19 Vaccine Immunity in Tissue and Blood

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand the effects of COVID-19 vaccines on the immune system and how the COVID-19 vaccines provide protection and induce long term memory. Adults who are receiving a COVID-19 vaccine will be invited to participate in this study.

Official Title
-----------------
Understanding COVID-19 Vaccine Immunity in Tissue and Blood

Conditions
-----------------
COVID-19 (Coronavirus Disease 2019)

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults 18yrs old and higher who are receiving a COVID-19 vaccine Exclusion Criteria: Pregnancy Patients with contraindications for lymph node biopsy Active cancer Current use of immunosuppression drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants<br>Adults who are receiving a COVID-19 vaccine | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Testing immune response to the COVID-19 vaccine over time |  | 1 day | 
| Testing immune response to the COVID-19 vaccine over time |  | 7 days | 
| Testing immune response to the COVID-19 vaccine over time |  | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Immunity, Vaccine
Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma

Study Overview
=================
Brief Summary
-----------------
Study of the relationship between hemodynamic stability and preoperative intravenous rehydration in patients with pheochromocytoma

Detailed Description
-----------------
All patients were subclassified into either the hemodynamic stability group (HS group) or the hemodynamic instability group (HU group) according to whether intraoperative hemodynamic instability occurred. Differences in data between the two groups were examined, and the risk factors for intraoperative hemodynamic instability were analyzed using logistic regression.

Official Title
-----------------
Clinical Study of Abandonment of Intravenous Volume Expansion After Preoperative Use of α-blockers in Patients With Adrenal Pheochromocytoma

Conditions
-----------------
Adrenal Pheochromocytoma, Hemodynamic

Intervention / Treatment
-----------------
* Drug: Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of adrenal pheochromocytoma Must be able to swallow tablets Exclusion Criteria: Bilateral or multiple pheochromocytomas. Ectopic pheochromocytoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: PXB combined with venous dilation group<br>Use of PXB combined with intravenous volume expansion during preoperative preparation in patients with pheochromocytoma | |
| Experimental: PXB group<br>PXB alone during preoperative preparation in patients with pheochromocytoma | Drug: Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma<br>* Abandonment of intravenous volume expansion with alpha-blockers during preoperative preparation in patients with pheochromocytoma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraoperative mean arterial pressure | an intraoperative mean arterial pressure <60 mmHg is considered to be hemodynamically unstable | During surgery |
Portable Ultrasound to Predict Heart Failure Readmission Risk

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to use a handheld ultrasound to assess patients with congestive heart failure (CHF) to see if the ultrasound can help predict readmission to the hospital. The study will include patients who are admitted to the hospital for CHF. Participants will have two ultrasounds at hospital discharge and at a follow up visit.

Detailed Description
-----------------
The purpose of this research is to see if a portable ultrasound can help predict readmission to the hospital for patients who are admitted to the hospital for CHF. The study will enroll patients who take part in Mobile Integrated Healthcare as part of their routine care. Participants will have two ultrasounds. The first ultrasound will be at hospital discharge. Between seven to ten days after hospital discharge participants will be visited at their home in follow-up as the usual standard of care for Mobile Integrated Healthcare. At this visit participants will have a second ultrasound. Participants will be followed for one year for hospital readmission.

Official Title
-----------------
Utility and Feasibility of Prehospital Portable Ultrasound to Predict Heart Failure Readmission Risk

Conditions
-----------------
Heart Failure, Patient Readmission

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary admission diagnosis is listed as congestive heart failure, with an acute component of decompensation. Age greater than 18 years. Principal residence within the geographic reach of our MIH program. Exclusion Criteria: pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasound<br>Ultrasound at hospital discharge and at follow up in 7-10 days | Diagnostic Test: Ultrasound<br>* Ultrasound at hospital discharge and at follow up at 7-10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital Readmission | Hospital readmission within 30 days of discharge | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrasound
Efficacy and Safety of Apremilast in Psoriasis

Study Overview
=================
Brief Summary
-----------------
Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.

Official Title
-----------------
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Drug: Apremilast 30mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed patients of chronic plaque psoriasis patients applicant for oral or parenteral treatments and for light therapy patients not responding to topical treatments Exclusion Criteria: Patients who show hypersensitive reactions to apremilast to any of its inactive component Pregnancy Lactating mothers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Apremilast 30 mg twice daily<br> | Drug: Apremilast 30mg<br>* Apremilast 30mg twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psoriasis area and severity index |  | 16 weeks | 
| body surface area |  | 16 weeks |
Effect of HIIT Vs Moderate Intensity Aerobic Exercise on Insulin Resistance in Type 2 DM

Study Overview
=================
Brief Summary
-----------------
Comparing between the efficacy of high intensity interval training and moderate intensity aerobic exercises on insulin resistance in type 2 Diabetes Mellitus.

Detailed Description
-----------------
The study aims at differentiating between high intensity interval training and moderate intensity continuous aerobic exercise in terms of their effect of Insulin resistance in patients diagnosed with type 2 Diabetes Mellitus. All participants will have lab analysis for Serum Homa-IR prior to intervention and after 1 month of treatment.

Official Title
-----------------
Effect of High Intensity Interval Training Versus Moderate Intensity Aerobic Exercise on Insulin Resistance in Type 2 Diabetes

Conditions
-----------------
Diabetes Mellitus, Insulin Resistance

Intervention / Treatment
-----------------
* Other: High intensity interval training
* Other: moderate intensity aerobic exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes Mellitus Patients. Diagnosed for more than 1 years at the time of the study. Patients with fair control of blood glucose using hypoglycemic drugs Exclusion Criteria: Type 1 (Insulin Dependant) Diabetes Mellitus patients. Patients with disability that can't perform exercises. Patient with known Cardiovascular diseases. Patients with kidney/liver diseases

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High intensity interval training (group A)<br>30 Diabetic patients (Type 2 Diabetes Mellitus) will receive high intensity interval training | Other: High intensity interval training<br>* Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest<br>|
| Experimental: moderate intensity aerobic exercise (group B)<br>30 Diabetic patients (Type 2 Diabetes Mellitus) will receive moderate intensity aerobic exercise | Other: moderate intensity aerobic exercise<br>* Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin Resistance (Homa-IR) | Serum insulin resistance indicator (Homa-IR) | 1 month |